News Releases
Financial Results
| Three Months Ended |
Year Ended |
|||||||||||||||||
| Increase/ | Increase/ | |||||||||||||||||
| (Millions, except per share results) | 2011 | 2010 | (Decrease) | 2011 | 2010 | (Decrease) | ||||||||||||
| Revenue | $ | 721.5 | $ | 749.2 | (3.7 | )% | $ | 2,799.4 | $ | 2,969.2 | (5.7 | )% | ||||||
| Segment Profit | 63.2 | 61.2 | 3.3 | % | 270.4 | 291.1 | (7.1 | )% | ||||||||||
| Net Income | 29.7 | 32.9 | (9.7 | )% | 129.6 | 138.7 | (6.6 | )% | ||||||||||
| Earnings per Share | 1.05 | 0.95 | 10.5 | % | 4.17 | 4.03 | 3.5 | % | ||||||||||
As of
"Magellan had a strong fourth quarter, which completed a successful 2011," said René Lerer, M.D., chairman and chief executive officer. "In addition to achieving solid financial results, our accomplishments during the year included attracting new customers, retaining existing customers and implementing a focused growth strategy in
"We are moving aggressively in our two leading strategic initiatives — expanding more broadly into the
"There is a significant level of activity across our business lines to achieve growth, retention and profitability objectives, while maintaining our track record of product innovation," said Karen S.
"Throughout 2012, we will intensify our effort to renew key accounts and accelerate initiatives to improve business outcomes. We have already taken decisive steps to position Magellan to be successful for the rebid of the
Outlook
"Overall we completed a strong 2011, exceeding our segment profit guidance for the year," said
"We are reaffirming our guidance for 2012, which calls for net revenue in the range of
Earnings Results Conference Call
Management will host a conference call at
About
Cautionary Statement
This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2012 net revenue, net income, segment profit, earnings per share, and strategy. These statements are based on management's analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "may," "should," "could," "estimate," "intend" and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company's customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company's risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for
| CONSOLIDATED STATEMENTS OF INCOME | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended |
Years Ended December 31, | |||||||||||||||
| 2010 |
2011 (1) |
2010 |
2011 (1) |
|||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Net revenue | $ | 749,210 | $ | 721,464 | $ | 2,969,240 | $ | 2,799,400 | ||||||||
| Cost and expenses: | ||||||||||||||||
| Cost of care | 491,668 | 461,527 | 1,907,985 | 1,784,724 | ||||||||||||
| Cost of goods sold | 52,492 | 64,479 | 218,630 | 232,038 | ||||||||||||
| Direct service costs and other operating expenses (2) | 147,130 | 136,250 | 566,582 | 529,634 | ||||||||||||
| Depreciation and amortization | 13,075 | 15,335 | 54,682 | 58,623 | ||||||||||||
| Interest expense | 482 | 1,080 | 2,233 | 2,502 | ||||||||||||
| Interest income | (809 | ) | (516 | ) | (3,275 | ) | (2,781 | ) | ||||||||
| 704,038 | 678,155 | 2,746,837 | 2,604,740 | |||||||||||||
| Income before income taxes | 45,172 | 43,309 | 222,403 | 194,660 | ||||||||||||
| Provision for income taxes | 12,244 | 13,570 | 83,744 | 65,037 | ||||||||||||
| Net income | 32,928 | 29,739 | 138,659 | 129,623 | ||||||||||||
| Other comprehensive (loss) income | (126 | ) | 143 | (105 | ) | (159 | ) | |||||||||
| Comprehensive income | $ | 32,802 | $ | 29,882 | $ | 138,554 | $ | 129,464 | ||||||||
| Weighted average number of common shares outstanding — basic | 33,971 | 27,724 | 33,779 | 30,478 | ||||||||||||
| Weighted average number of common shares outstanding — diluted | 34,730 | 28,300 | 34,441 | 31,058 | ||||||||||||
| Net income per common share — basic | $ | 0.97 | $ | 1.07 | $ | 4.10 | $ | 4.25 | ||||||||
| Net income per common share — diluted | $ | 0.95 | $ | 1.05 | $ | 4.03 | $ | 4.17 | ||||||||
|
(1) |
For a more detailed discussion of Magellan's results for the year ended |
|
|
(2) |
Includes stock compensation expense of |
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (In thousands) | |||||||||
| Years Ended December 31, | |||||||||
| 2010 |
2011 (1) |
||||||||
| Cash flows from operating activities: | |||||||||
| Net income | $ | 138,659 | $ | 129,623 | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Depreciation and amortization | 54,682 |
|
58,623 | ||||||
| Non-cash interest expense | 569 | 1,033 | |||||||
| Non-cash stock compensation expense | 15,102 | 17,418 | |||||||
| Non-cash income tax expense | 42,251 | 8,308 | |||||||
| Non-cash amortization on investments | 10,155 | 12,309 | |||||||
|
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses: |
|||||||||
| Restricted cash (2) | 42,925 | (69,060 | ) | ||||||
| Accounts receivable, net | 3,262 | (15,609 | ) | ||||||
| Inventory | (2,347 | ) | (11,657 | ) | |||||
| Other assets | (14,847 | ) | (5,672 | ) | |||||
| Accounts payable and accrued liabilities | 14,447 | (7,251 | ) | ||||||
| Medical claims payable and other medical liabilities | 3,638 | (7,905 | ) | ||||||
| Other | 445 | 1,843 | |||||||
| Net cash provided by operating activities | 308,941 | 112,003 | |||||||
| Cash flows from investing activities: | |||||||||
| Capital expenditures | (46,162 | ) | (54,394 | ) | |||||
| Acquisitions and investments in businesses, net of cash acquired | - | (376 | ) | ||||||
| Purchase of investments | (291,289 | ) | (259,552 | ) | |||||
| Maturity of investments | 226,957 | 330,583 | |||||||
| Net cash (used in) provided by investing activities | (110,494 | ) | 16,261 | ||||||
| Cash flows from financing activities: | |||||||||
| Payments on long-term debt and capital lease obligations | (1,120 | ) | (559 | ) | |||||
| Payments to acquire treasury stock | (149,805 | ) | (407,645 | ) | |||||
| Proceeds from issuance of equity | - | 20,000 | |||||||
| Proceeds from exercise of stock options and warrants | 92,876 | 41,796 | |||||||
| Tax benefit from exercise of stock options and vesting of stock awards | 1,121 | 2,038 | |||||||
| Other | (847 | ) | (1,211 | ) | |||||
| Net cash used in financing activities | (57,775 | ) | (345,581 | ) | |||||
| Net increase (decrease) in cash and cash equivalents | 140,672 | (217,317 | ) | ||||||
| Cash and cash equivalents at beginning of period | 196,507 | 337,179 | |||||||
| Cash and cash equivalents at end of period | $ | 337,179 | $ | 119,862 | |||||
|
(1) |
The Company's Annual Report on Form 10-K for the year ended |
|
|
(2) |
Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. During the year ended |
| CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| Three Months Ended |
Years Ended December 31, | |||||||||||||||
| 2010 | 2011 (1) | 2010 |
2011 (1) |
|||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Net revenue | ||||||||||||||||
| - Commercial | $ | 164,267 | $ | 136,694 | $ | 652,221 | $ | 561,780 | ||||||||
| - Public Sector | 360,512 | 384,755 | 1,442,093 | 1,459,659 | ||||||||||||
| - Radiology Benefits Management | 123,006 | 85,856 | 454,105 | 344,335 | ||||||||||||
| - Specialty Pharmaceutical Management | 65,906 | 82,555 | 270,646 | 295,943 | ||||||||||||
| - |
54,980 | 52,831 | 176,283 | 220,453 | ||||||||||||
| - Elimination (2) | (19,461 | ) | (21,227 | ) | (26,108 | ) | (82,770 | ) | ||||||||
| Total net revenue | 749,210 | 721,464 | 2,969,240 | 2,799,400 | ||||||||||||
| Cost of care | ||||||||||||||||
| - Commercial | 99,375 | 78,240 | 365,115 | 314,178 | ||||||||||||
| - Public Sector (2) | 315,847 | 337,870 | 1,246,779 | 1,271,532 | ||||||||||||
| - Radiology Benefits Management | 78,305 | 47,509 | 298,516 | 205,240 | ||||||||||||
| - |
17,602 | 19,135 | 23,683 | 76,544 | ||||||||||||
| - Elimination (2) | (19,461 | ) | (21,227 | ) | (26,108 | ) | (82,770 | ) | ||||||||
| Total cost of care | 491,668 | 461,527 | 1,907,985 | 1,784,724 | ||||||||||||
| Cost of goods sold - Specialty Pharmaceutical Management | 52,492 | 64,479 | 218,630 | 232,038 | ||||||||||||
| Direct service costs and other operating expenses | ||||||||||||||||
| - Commercial | 40,938 | 39,258 | 156,278 | 152,760 | ||||||||||||
| - Public Sector | 17,018 | 17,024 | 67,577 | 67,227 | ||||||||||||
| - Radiology Benefits Management | 20,067 | 14,401 | 67,672 | 61,681 | ||||||||||||
| - Specialty Pharmaceutical Management | 6,831 | 5,686 | 26,368 | 24,344 | ||||||||||||
| - |
29,757 | 25,198 | 124,312 | 103,254 | ||||||||||||
| - Corporate | 32,519 | 34,683 | 124,375 | 120,368 | ||||||||||||
| Total direct service costs and other operating expenses | 147,130 | 136,250 | 566,582 | 529,634 | ||||||||||||
| Stock compensation expense (3) | ||||||||||||||||
| - Commercial | (158 | ) | (162 | ) | (714 | ) | (839 | ) | ||||||||
| - Public Sector | (160 | ) | (218 | ) | (714 | ) | (872 | ) | ||||||||
| - Radiology Benefits Management | (362 | ) | (325 | ) | (1,485 | ) | (1,563 | ) | ||||||||
| - Specialty Pharmaceutical Management | (59 | ) | (54 | ) | (424 | ) | (693 | ) | ||||||||
| - |
2 | (24 | ) | (74 | ) | (124 | ) | |||||||||
| - Corporate | (2,535 | ) | (3,227 | ) | (11,691 | ) | (13,327 | ) | ||||||||
| Total stock compensation expense | (3,272 | ) | (4,010 | ) | (15,102 | ) | (17,418 | ) | ||||||||
| Segment profit (loss) | ||||||||||||||||
| - Commercial | 24,112 | 19,358 | 131,542 | 95,681 | ||||||||||||
| - Public Sector | 27,807 | 30,079 | 128,451 | 121,772 | ||||||||||||
| - Radiology Benefits Management | 24,996 | 24,271 | 89,402 | 78,977 | ||||||||||||
| - Specialty Pharmaceutical Management | 6,642 | 12,444 | 26,072 | 40,254 | ||||||||||||
| - |
7,619 | 8,522 | 28,362 | 40,779 | ||||||||||||
| - Corporate and Elimination | (29,984 | ) | (31,456 | ) | (112,684 | ) | (107,041 | ) | ||||||||
| Total segment profit | $ | 61,192 | $ | 63,218 | $ | 291,145 | $ | 270,422 | ||||||||
|
Reconciliation of segment profit to income before income taxes: |
||||||||||||||||
| Segment profit | $ | 61,192 | $ | 63,218 | $ | 291,145 | $ | 270,422 | ||||||||
| Stock compensation expense | (3,272 | ) | (4,010 | ) | (15,102 | ) | (17,418 | ) | ||||||||
| Depreciation and amortization | (13,075 | ) | (15,335 | ) | (54,682 | ) | (58,623 | ) | ||||||||
| Interest expense | (482 | ) | (1,080 | ) | (2,233 | ) | (2,502 | ) | ||||||||
| Interest income | 809 | 516 | 3,275 | 2,781 | ||||||||||||
| Income before income taxes | $ | 45,172 | $ | 43,309 | $ | 222,403 | $ | 194,660 | ||||||||
|
(1) |
The Company's Annual Report on Form 10-K for the year ended |
|
|
(2) |
Effective |
|
|
(3) |
Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis. |
Media Contact:
David
dwcarter@magellanhealth.com
or
Investor Contact:
rshapiro@magellanhealth.com
Source:
News Provided by Acquire Media
